Achieve Life Sciences Q3 net loss $6.7M; ORCA-2 topline data expected H1 2022

ACHIEVE LIFE SCIENCES, INC.

2022-Q3 EPS reported -$3.39

Cash equivalents $33.4M; total operating expenses $6.7M for Q3, $26.0M for 9 months.
ORCA-2 Phase 3 completed treatment; topline data expected first half 2022.
ORCA-3 Phase 3 enrollment of ~750 subjects to start by early 2022.
FDA accepted IND for cytisinicline e-cigarette cessation trial; ORCA-V1 to start Q2 2022.
Two U.S. patents issued for 3.0 mg TID dosing regimen, expiring 2040.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.